Mycobacterial disease in patients with rheumatic disease

Nature Clinical Practice Rheumatology

Volumn 4, Issue 12, 2008, Pages 649-656

  van Ingen, Jakko ^a,b   Boeree, Martin J ^a,b   Dekhuijzen, P N Richard ^a   van Soolingen, Dick ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIRHEUMATIC AGENT; ATLIZUMAB; CD20 ANTIBODY; CD4 ANTIBODY; CERTOLIZUMAB PEGOL; ETANERCEPT; ETHAMBUTOL; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 23 ANTIBODY; ISONIAZID; JANUS KINASE INHIBITOR; MACROLIDE; METALLOPROTEINASE INHIBITOR; METHOTREXATE; PLACEBO; PREDNISONE; PROTEIN INHIBITOR OF ACTIVATED STAT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN; RITUXIMAB; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ATYPICAL MYCOBACTERIOSIS; BACTERIUM CULTURE; BACTERIUM DETECTION; BEHCET DISEASE; BIOLOGICAL THERAPY; CLINICAL TRIAL; DERMATOMYOSITIS; DRUG DOSE COMPARISON; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; HEPATITIS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERVERTEBRAL DISK DEGENERATION; LOW DRUG DOSE; LUNG TUBERCULOSIS; MONOTHERAPY; MYCOBACTERIOSIS; NONHUMAN; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; PSOAS ABSCESS; PSORIASIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCREENING TEST; SKIN TUBERCULOSIS; TENOSYNOVITIS; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTIRHEUMATIC AGENTS; HUMANS; MASS SCREENING; MYCOBACTERIUM INFECTIONS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 57149091953     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0949     Document Type: Review

References (57)

1. Winthrop KL (2006) Serious infections with antirheumatic therapy: Are biologicals worse? Ann Rheum Dis 65 (suppl 3): 54-57
2. Griffith DE et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416
3. Salvana EM et al. (2007) Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients. J Infect 55: 484-487
4. Winthrop KL et al. (2008) Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the Emerging Infections Network. Clin Infect Dis 46: 1738-1740
5. Gardam MA et al. (2003) Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 3: 148-155
6. Roach DR et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168: 4620-4627
7. Saliu OY et al. (2006) Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194: 486-492
8. Salliot C et al. (2008) Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis [doi:10.1136/ard.2007.083188]
9. Fleischmann RM et al. (2006) Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1006-1012
10. Brassard P et al. (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43: 717-722
11. Settas LD et al. (2007) Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). J Clin Rheumatol 13: 219-220
12. Weinblatt M et al. (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54: 2807-2816
13. Bigbee CL et al. (2007) Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice. Arthritis Rheum 56: 2557-2565
14. Riley P et al. (2008) Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 47: 877-880
15. Gottlieb AB et al. (2004) Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51: 534-542
16. Baughman RP et al. (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174: 795-802
17. Naganuma M et al. (2008) Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet's disease. Inflamm Bowel Dis 14: 1259-1264
18. The Lenercept Multiple Sclerosis study group and the University of British Columbia MS/MRI analysis group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465
19. Rennard SI et al. (2007) The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 926-934
20. Kay J et al. (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58: 964-975
21. Schreiber S et al. (2007) Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250
22. Smolen JS et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997
23. Saunders BM et al. (2000) Interleukin-6 induces early gamma interferon production in the infected lung but is not required for generation of specific immunity to Mycobacterium tuberculosis infection. Infect Immun 68: 3322-3326
24. Nagabhushanam V et al. (2003) Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 171: 4750-4757
25. Lubberts E (2008) IL-17/Th17 targeting: On the road to prevent chronic destructive arthritis? Cytokine 41: 84-91
26. McInnes IB et al. (2005) Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 31-39
27. Khader SA and Cooper AM (2008) IL-23 and IL-17 in tuberculosis. Cytokine 41: 79-83
28. Malemud CJ and Miller AH (2008) Pro-inflammatory cytokine-induced SAPK/ MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 12: 171-183
29. Haverkamp MH et al. (2006) Human host genetic factors in nontuberculous mycobacterial infection: Lessons from single gene disorders affecting innate and adaptive immunity and lessons from molecular defects in interferon-gamma-dependent signaling. Microbes Infect 8: 1157-1166
30. Murphy G and Nagase H (2008) Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: Destruction or repair? Nat Clin Pract Rheumatol 4: 128-135
31. Taylor JL et al. (2006) Role for matrix metalloproteinase 9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect Immun 74: 6135-6144
32. Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α neutralizing agent. N Engl J Med 345 1098-1104
33. Gómez-Reino JJ et al. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 48: 2122-2127
34. Wallis RS et al. (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261-1265
35. Maimon N et al. (2007) Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 62: 739-740
36. Yim K et al. (2004) Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand J Infect Dis 36: 150-154
37. Chopra N et al. (2002) Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 8: 265-268
38. Thomas JE et al. (2006) Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. Hawaii Med J 65: 12-15
39. van Ingen J et al. (2007) Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheum 3: 414-419
40. van Ingen J et al. (2008) Clinical relevance of Mycobacterium xenopi isolation and its determinants in the Netherlands. Emerg Infect Dis 14: 385-389
41. van Ingen J et al. (2008) Clinical relevance of Mycobacterium szulgai in the Netherlands. Clin Infect Dis 46: 1200-1205
42. Winthrop KL et al. (2007) Nontuberculous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3: E1
43. Bala S et al. (1998) Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice. Antimicrob Agents Chemother 42: 2336-2341
44. Centers for Disease Control and Prevention (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 53: 683-686
45. British Thoracic Society (BTS) Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60: 800-805
46. Pai M et al. (2004) Interferon-gamma assays in the immunodiagnosis of tuberculosis: A systematic review. Lancet Infect Dis 4: 761-776
47. Sellam J et al. (2007) Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 66: 1610-1615
48. Matulis G et al. (2008) Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 67: 84-90
49. Sorensen AL et al. (1995) Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect Immun 63: 1710-1717
50. Sichletidis L et al. (2006) Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10: 1127-1132
51. Karakousis PC et al. (2008) Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 61: 323-331
52. Research Committee of the British Thoracic Society (2008) Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in the treatment of opportunist mycobacterial pulmonary diseases and an assessment of the value of immunotherapy with M. vaccae: A pragmatic, randomised trial by The British Thoracic Society. Thorax 63: 627-634
53. Garcia Vidal C et al. (2005) Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 40: 756-759
54. Wallis RS (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41: 201-208
55. Aslanidis S et al. (2008) Is it safe to readminister tumor necrosis factor antagonists following tuberculosis flare? Arthritis Rheum 58: 327-328
56. Matsumoto T et al. (2006) Infliximab for rheumatoid arthritis in a patient with tuberculosis. N Engl J Med 355: 740-741
57. Saag KG et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59: 762-784